FIELD: medicine.
SUBSTANCE: group of inventions refers to nephrology, and can be used for preserving the renal function in an individual in need thereof who suffers gout, acute gouty arthritis, chronic gouty arthropathy, chalky gout. That is ensured by administering an effective amount of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazol-5-carboxyl acid or a pharmaceutically acceptable salt thereof. The renal function is elevated by at least one of blood serum creatinin, creatinin clearance and glomerular filtration rate, wherein the individual's glomerular filtration rate (GFR) is maintained at the level of approximately 75% or more as compared to an individual's initial glomerular filtration rate (GFR).
EFFECT: using the given inventions enables preserving the renal function.
2 cl, 6 dwg, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED USE OF COMPOUND A AND COMPOUND B FOR PRODUCTION OF DRUGS FOR TREATMENT OF GOUT OR HYPERURICEMIA | 2019 |
|
RU2783862C1 |
| THERAPEUTIC OR PREVENTIVE AGENT FOR TUMOUR LYSIS SYNDROME | 2013 |
|
RU2627591C2 |
| METHODS AND COMPOSITIONS FOR TREATING HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA | 2012 |
|
RU2603050C2 |
| MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FEBUXOSTAT | 2011 |
|
RU2602188C2 |
| INTRACELLULAR ATP INCREASING COMBINATION | 2016 |
|
RU2728722C2 |
| USE OF DERIVATIVES CONTAINING THE C-O-P BONDS IN THE PATIENTS WITH RENAL INSUFFICIENCY | 2014 |
|
RU2725626C2 |
| CRYSTAL OF AZOLE BENZENE DERIVATIVE | 2015 |
|
RU2675854C2 |
| SODIUM SALT OF THE URIC ACID TRANSPORTER INHIBITOR AND ITS CRYSTALLINE FORM | 2016 |
|
RU2719484C2 |
| ALPORT SYNDROME TREATMENT OPTIONS | 2018 |
|
RU2791694C2 |
| TETRAZOLE COMPOUNDS FOR REDUCING CONCENTRATION OF URIC ACID | 2009 |
|
RU2522458C2 |
